The Company

Palo Alto Health Sciences, Inc. is a privately held Silicon Valley digital therapeutic company at the forefront of revolutionizing behavioral healthcare with evidence based, at-home, drug-free solutions. Our product, Freespira®, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic.

Our Mission

To improve the quality-of-life of people suffering from debilitating panic attacks associated with chronic behavioral and medical conditions; reducing medical costs and supporting the appropriate utilization of valuable healthcare resources.

Click to go to Newsroom

Leadership Team

Board of Directors

Russell Siegelman Chairman
Russell Siegelman has spent over twenty years in business and technology as a manager, investor and director. As a Lecturer at Stanford Business School he teaches Startup Garage, Product Launch and Starting and Growing a Social Venture. Starting in 1996, Russell spent eleven years as a Partner at Kleiner Perkins Caufield & Byers, where he invested in consumer and technology related technologies and markets, including software, electronic commerce, Web services, semiconductors, mobile systems, media and telecommunications.
Ned Scheetz
Ned Scheetz founded Aphelion Capital in 2005 and has over 20 years of healthcare investing experience. Prior to forming Aphelion, Ned was a Partner and Managing Director with Piper Jaffray Ventures (PJV), focusing on investments in emerging medical technology companies. Ned joined PJV from Janus Capital, where he was a Senior Research Analyst covering both healthcare and internet investments. Ned has served on numerous private company boards over his career. He currently serves on the Board of Directors for Aardvark Medical, ClearFlow, CyMedica, Explorer Surgical, Mercator Medsystems, and Palo Alto Health Sciences.
Amy Perry
Amy serves as CEO, Hospital Division, and Senior Vice President, Integrated Care Delivery, at Atlantic Health System, a $2.8 billion health care organization based in Morristown, New Jersey. Amy is a strategic leader with an impressive background in finance and operations, clinical quality and academic medicine, and health policy and governance. She has a strong track record of identifying opportunities for growth and innovation, as well as substantial experience improving outcomes, lowering costs, transitioning to value-based payments, and implementing population health strategies.
Debra Reisenthel
Debra is founding President and CEO of Palo Alto Health Sciences. Since joining PAHS in 2013, Debra has grown the company by establishing relationships with leading Payers and Employers while overseeing the development and launch of the next generation Freespira treatment for panic. She has led the programs to expand PAHS’ evidence base with clinical trials for PTSD and adolescents. In 2020, Debra was elected to the Board of Directors of Digital Therapeutics Alliance (DTA), the trade organization focused on advocating for digital therapeutics to payers, providers and regulatory agencies.

Business Advisors